Efficacy and safety of subcutaneous administration of ceftazidime as a salvage therapy in geriatrics: a case report.
antimicrobial chemotherapy
ceftazidime
geriatrics
subcutaneous route
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
13
08
2019
revised:
30
09
2019
accepted:
07
11
2019
pubmed:
12
11
2019
medline:
21
4
2021
entrez:
12
11
2019
Statut:
ppublish
Résumé
Ceftazidime is a third-generation cephalosporin used for the treatment of Gram-negative bacteria only approved for parenteral use by intravenous and intramuscular route. In some clinical situations, off-label subcutaneous injection could be a salvage route for the administration of antibiotics, especially in geriatrics, despite the paucity of evidence about efficacy and safety. We report a case of a successful and well-tolerated subcutaneous ceftazidime therapy in a 90-year-old woman for the treatment of an acute urinary tract infection caused by Pseudomonas aeruginosa with therapeutic drug monitoring data.
Substances chimiques
Anti-Bacterial Agents
0
Ceftazidime
9M416Z9QNR
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-524Informations de copyright
© 2019 Société Française de Pharmacologie et de Thérapeutique.
Références
Colin E., Baldolli A., Verdon R., Saint-lorant G. Subcutaneously administered antibiotics. Med. Mal. Infect. (2019). pii: S0399-077X(18)30775-3. https://doi.org/10.1016/j.medmal.2019.06.007
European Medicine agency. Committee for medicinal products for human use (CHMP). Fortum - Article 30 referral - Annex III (2010) https://www.ema.europa.eu/en/documents/referral/fortum-article-30-referral-annex-iii_en.pdf (Accessed July 15, 2019).
Guery B., Menichetti F., Anttila V.J. et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect. Dis. (2018) 18 296-307.
European Committee on Antimicrobial Susceptibility Testing. Data from the EUCAST MIC distribution website. http://www.eucast.org (Acceded July 12, 2019).
Spellberg B., Rice L.B. Duration of antibiotic therapy: shorter is better. Ann. Intern. Med. (2019) 171 210-211.
Fonzo-Christe C., Vukasovic C., Wasilewski-Rasca A.F., Bonnabry P..Subcutaneous administration of drugs in the elderly: Survey of practice and systematic literature review. Palliat. Med. (2005) 19 208-219.
Forestier E., Paccalin M., Roubaud-Baudron C., Fraisse T., Gavazzi G., Gaillat J. Subcutaneously administered antibiotics: a national survey of current practice from the French Infectious Diseases (SPILF) and Geriatric Medicine (SFGG) society networks. Clin. Microbiol. Infect. (2015) 21 370 e1-3.
Roubaud-Baudron C., Forestier E., Fraisse T. et al. Tolerance of subcutaneously administered antibiotics: a French national prospective study. Age Ageing (2017) 46 151-155.
Walker P., Neuhauser M.N., Tam V.H. et al.Subcutaneous administration of cefepime. J. Pain Symptom. Manage. (2005) 30 170-174.
European Medicine agency. Committee for medicinal products for human use (CHMP) WC500167082. (2014) Rocephin and associated names. https://www.ema.europa.eu/en/documents/referral/rocephin-article-30-referral-assessment-report_en.pdf (Accessed July 15, 2019).
Ebihara T., Oshima S., Yasuda Y. et al.A survey of subcutaneous blood flow in patients with SMID and subcutaneous ceftazidime administration using mentholated warm compresses in healthy subjects. J. Int. Med. Res (2016) 44 248-257.
Duron D., Chanoine S., Peron M. et al. A successful antibiotic treatment by a new administration route: a case report of a subcutaneous administration of ceftazidime and tobramycin. Fundam. Clin. Pharmacol. (2019) 6 703-706. https://doi.org/10.1111/fcp.12477